10 GHP Q3 2023 aving already successfully developed, produced, and marketed polyclonal antibodies that are now utilised in various life sciences research areas, SICGEN Antibodies is a company whose name has become synonymous with excellence in the field. Driven by the goal of being recognised worldwide as a global producer of its specialty antibodies, the collective has gone above and beyond to concoct new and astonishing antibodies that pose a variety of capabilities. One such example takes the form of antibodies against fluorescent proteins such as GFP, mCherry, and tdTomato. Having been featured in prestigious life science publications such as Nature, Cell, and Science, this product is just one of many that has garnered the unwavering attention of the wider community. When turning our attention to 2024, however, it appears that SICGEN Antibodies has only increased its pace. Since the start of the year, the company’s line has expanded to more than 300 products, each primarily used for research purposes, but still maintaining a focus on techniques such as Western Blotting, Immunofluorescence, and Immunocytochemistry. In addition to further applications in ELISA, immunoprecipitation, and other biochemical techniques, SICGEN Antibodies has certainly followed its forward momentum, without plans of ever slowing down. This is most likely a result of the collective’s avid passion for ongoing innovation – a quality that sees it continuously developing new antibody-related products. At present, SICGEN Antibodies supplies polyclonal antibodies to leading institutions both nationally and internationally, be they universities, research institutes, pharmaceutical manufacturers or biotechnology distributors – with its main markets consisting of those in North America, Europe, and the Far East. It achieves this through a combination of marketing methods, including direct sales, collaboration with countrywide distributors, and utilising the Feb24116 H Dedicated to the development, manufacturing, and marketing of polyclonal antibodies for Cell Biology research, SICGEN Antibodies is a multiaward-winning European company whose impact on the industry has been felt for over a decade. Created in 2009, and headquartered in the district of Coimbra, the company leverages cuttingedge biotechnologies in its avid pursuit of becoming the definitive global producer of high-quality polyclonal antibodies and antibody-related products and services. Partnered with its desire to do so at competitive prices, SICGEN Antibodies has truly captured the very essence of the market it seeks to champion. OEM system. In essence, SICGEN Antibodies relies on both the intrinsically impressive qualities of its products, in tandem with scientific papers that mention the use of its antibodies to prove its credibility, to thrive, and has allowed this very method to guide it through its consistent growth. Partnered with its commitment to continuous development, it’s unsurprising that SICGEN Antibodies has come such a long way since its inception. Whether it’s focused on creating, producing, and marketing new antibodies to address various gaps in the market, or expanding its reach to new customers in various other markets through the implementation of a free sample program and increased distribution channels, the company is clearly committed to achieving its goal. As expected from a holder of multiple accolades, each more impressive than the next, SICGEN Antibodies is well on its way to becoming a global producer of highquality polyclonal antibodies. Though it may seem like an ambitious venture, no company has displayed such avid determination quite like SICGEN Antibodies. Though the antibody industry has experienced significant growth in the past decade alone, with constant revelations emerging on a frequent basis, SICGEN Antibodies has remained at the very forefront of polyclonal antibody development. In doing so, it’s found a specialty for which it’s known, ultimately resulting in a fantastic market standing that’s sure to persist throughout the sector’s further evolution. We look forward to seeing how SICGEN Antibodies approaches the future of the antibody industry as it progresses further into 2024. Contact: José Ramalho Company: SICGEN Antibodies Web Address: www.sicgfen.pt Polyclonal Antibody Production Specialists of the Year 2024 & Client Service Excellence Award
RkJQdWJsaXNoZXIy MTUyMDQwMA==